Consolidated income Statement
Show table
€ million | Note | 2014 | 2013 |
---|---|---|---|
Sales | → 23 | 11,291.5 | 10,700.1 |
Royalty, license and commission income | → 24 | 209.3 | 395.0 |
Total revenues | 11,500.8 | 11,095.1 | |
Cost of sales1 | → 25 | – 3,526.4 | – 3,041.7 |
(of which: amortization of intangible assets)1 | (– 94.0) | (– 49.2) | |
Gross profit1 | 7,974.4 | 8,053.4 | |
Marketing and selling expenses1 | → 26 | – 3,104.9 | – 3,088.5 |
(of which: amortization of intangible assets)1 | (– 719.0) | (– 762.0) | |
Royalty, license and commission expenses | → 27 | – 537.5 | – 567.0 |
Administration expenses | → 28 | – 608.6 | – 562.4 |
Research and development costs1 | → 29 | – 1,703.7 | – 1,506.6 |
(of which: amortization of intangible assets)1 | (– 3.8) | (– 2.3) | |
Other operating expenses and income | → 30 | – 257.7 | – 718.1 |
Operating result (EBIT) | 1,762.0 | 1,610.8 | |
Financial result | → 31 | – 205.0 | – 222.2 |
Profit before income tax | 1,557.0 | 1,388.6 | |
Income tax | → 32 | – 392.2 | – 179.5 |
Profit after tax | 1,164.8 | 1,209.1 | |
of which attributable to Merck KGaA shareholders (net income) | 1,157.3 | 1,202.2 | |
of which attributable to non-controlling interests | → 33 | 7.5 | 6.9 |
Earnings per share (in €) | → 34 | ||
basic2 | 2.66 | 2.77 | |
diluted2 | 2.66 | 2.77 | |
|